Medicinal Cannabis and Central Nervous System Disorders

Area of Science:

• Pharmacology and Neuroscience
• Cannabinoid Therapeutics
• Central Nervous System Disorders

Background:

• Cannabinoids from cannabis show therapeutic promise for pain and neurological conditions.
• Medicinal cannabis use is increasingly accepted, yet lacks frontline therapeutic validation for CNS disorders.
• Over 100 compounds exist in cannabis, but research often focuses on Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD).

Purpose of the Study:

• To review preclinical and clinical evidence on medicinal cannabis for pathological pain, neurodegeneration, substance use, and anxiety disorders.
• To examine the therapeutic utility of purified THC, CBD, and other isolated cannabis compounds.
• To discuss studies utilizing whole-plant cannabis and identify challenges in clinical applications.

Main Methods:

• Systematic review of preclinical and clinical research.
• Analysis of studies focusing on purified Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
• Inclusion of studies using whole-plant cannabis products, noting compositional variability.

Main Results:

• Evidence supporting therapeutic use varies, with significant gaps in clinical validation for many CNS indications.
• Purified THC and CBD formulations offer more controlled research parameters compared to whole-plant products.
• Lack of detailed compositional analysis in whole-plant cannabis studies hinders definitive conclusions.

Conclusions:

• Medicinal cannabis, particularly purified THC and CBD, warrants further investigation for specific therapeutic applications.
• Challenges remain in standardizing cannabis products and advancing research for widespread clinical use.
• More rigorous clinical trials are needed to establish efficacy and safety for central nervous system disorders.